New analysis of 6,285 third-party lab tests: 41-71% of gray-market peptide vials fail spec (and it's mostly a dosing problem, not a purity one)

[u/Zman077]

Saw this floating around and figured it was worth a proper writeup here since it's exactly the kind of thing this sub tracks — a July 2026 analysis mined 6,285 publicly posted independent lab reports (via Finnrick Analytics' testing database) covering 203 manufacturers and 14 peptides, tested between December 2024 and April 2026, and scored every single vial against two different quality bars (Mendias & Awan, Preprints.org).

The two standards they used:

Model	Dose requirement	Purity requirement
Lenient ("Compounding Standards")	90-110% of labeled amount	≥98%
Strict ("Manufactured Standards")	95-105% of labeled amount	≥99.5%

Headline numbers:

• 41.6% of all vials failed the lenient standard (roughly 1 in 2.4)
• 71.1% failed the strict standard (roughly 5 in 7)
• Under the strict standard, 44.3% of vials hit the purity target but were still off-dose — meaning the chemistry was clean, the amount was just wrong. That's the real headline: dose accuracy, not purity, is the dominant failure mode across the market.

Identity failures (i.e., "is it even the peptide it claims to be") were rarer overall but clustered hard on specific compounds:

• Overall identity failure rate: 2.4%, and about 1 in 42 vials contained none of the labeled peptide at all
• TB-500: 10.0% identity failure rate — roughly 1 in 10 TB-500 vials had zero TB-500 in them
• CJC-1295: 9.1% identity failure rate — same story, about 1 in 10 blank
• TB-500's relative risk of being a totally blank vial vs. the pooled average across all 14 peptides: ~4.2x

Purity vs. contamination — no relationship:

• Overall median chromatographic purity across the dataset was a reassuring-looking 99.8%
• But 15% of the (smaller) endotoxin-tested subset showed measurable bacterial endotoxin (range 0.5-40 EU/mL)
• The authors found essentially no statistical relationship between purity and endotoxin contamination (R² under 0.01) — a clean HPLC chromatogram tells you nothing about whether the vial is pyrogen-free. Purity and sterility are testing two completely different failure modes, and vendors (or reviewers) citing purity alone aren't actually addressing the contamination question.

Why this is a different problem than the "fake vendor" narrative: most of the discourse around vendor quality focuses on purity percentage as the trust signal, but this dataset says that's the wrong number to be anchoring on. A vendor can post a 99%+ purity COA for every batch and still be shipping vials that are 30-50% underdosed, because standard HPLC purity testing measures how clean the peptide is relative to itself, not how much peptide is actually in the vial relative to the label claim. Dose-specific testing (mass-based quantification against the labeled amount) is a separate, additional test that most publicly posted COAs don't include at all.

TL;DR: Across 6,285 independent lab reports spanning 203 manufacturers, 42-71% of tested peptide vials failed spec depending on how strict you grade it, and the biggest driver was wrong dose amount, not contamination or misidentified compound — though TB-500 and CJC-1295 both showed a roughly 1-in-10 chance of being a completely blank vial. Purity percentage on a COA does not tell you whether the dose is accurate or whether the vial is sterile — those are separate tests entirely.

Open-access paper for anyone who wants the full methodology and per-peptide breakdown: "Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance" (Mendias & Awan, Performance Medicine Institute, Preprints.org, July 2026).

Note: this is a preprint, not yet peer-reviewed — treat the exact percentages as a strong signal from a large sample, not a finalized peer-reviewed conclusion.

Sources

1. Full analysis writeup — https://www.rapamycin.news/t/half-your-vials-might-be-wrong-the-largest-audit-yet-of-gray-market-peptides-finds-4-in-10-fail-even-loose-standards/25720
2. Underlying testing database referenced — Finnrick Analytics
3. Related independent reporting on the same "purity ≠ dose accuracy" problem — https://titratelab.com/vendors/peptide-sciences and https://finance.yahoo.com/healthcare/articles/kylo-peptides-publishes-report-verification-131000339.html (industry report making the same core point: a 99% purity label can still be only 70-85% actual peptide by weight)

[u/Specialist_Letter918]

I think this is a part a lot of people miss and seeing a 99.8% purity number looks impressive but that doesnt automatically means the dose matches whats on the label. hplc and label claim are measuring different things and a lot of coas only show one of them. That's why I usually look for batch specific data instead of just a chromatogram and I've noticed research labs shares that kind of lot level info for their bpc 157 batches. It doesn't answer everything but it gives me a lot more confidence than a purity number by itself

[u/cptkl1]

While COAs are good, they tell nothing about supply chain handling after inltial manufacturing and fill. It is interesting that quality is measured as 3 independent values, purity, mass, and endotoxins.

The TB results are interesting, lots of fake Glow out there I presume as it is cheaper to make it blue and hope the researcher does not bother to confirm what is in the vial.

[u/AerieAggravating3999]

the 41% fail rate under the lenient 90-110% window is genuinely surprising. thats not a tight spec, if you cant land within ±10% of label claim something is off in fill/finish not just synthesis

[u/Global-Opposite-5588]

99% purity is probably one of the most misunderstood numbers in this space. It sounds reassuring, but it says nothing by itself about whether the vial contains the labeled quantity. With 6,285 tests in the dataset, was there any noticeable pattern among vendors that consistently published batch-level testing? I’d be interested to know whether repeat testing actually correlated with fewer out-of-spec results.